The Marginal Zone Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Marginal Zone Lymphoma Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Marginal Zone Lymphoma Treatment.
-
Marginal Zone Lymphoma key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Marginal Zone Lymphoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample Pages @ https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight
Marginal Zone Lymphoma Therapeutics Landscape
The Marginal Zone Lymphoma Therapeutics Market is categorized into three types based on the line of therapies, i.e., first-line, second-line, and third-line of therapies. Treatment selection for a patient with Marginal Zone Lymphoma (MZL) depends on the type, stage, and location of the disease.
Several pharmaceutical key players have taken the initiative to meet the unmet needs of the present situation of the Marginal Zone Lymphoma market. Some of the key players are in the late and mid clinical development stages with their leading drug candidates. The launch of emerging products will fuel the Marginal Zone Lymphoma market growth.
Some of the key companies in the Marginal Zone Lymphoma Therapeutics Market include:
-
AbbVie
-
ArQule
-
AstraZeneca
-
Bayer
-
BeiGene
-
Bristol-Myers Squibb
-
Celgene Corporation
-
Cellectar Biosciences
-
Eli Lilly
-
Gilead Sciences
-
InnoCare Pharma
-
Innovent Biologics
-
Janssen Biotech
-
Loxo Oncology
-
MEI Pharma
-
Merck
-
NantKwest/ImmunityBio
-
Nordic Nanovector
-
Roche Pharma
-
TG Therapeutics
-
TriSalus Life Sciences
-
Verastem/Secura Bio
And many others
Marginal Zone Lymphoma Therapies covered in the report include:
-
Revlimid (lenalidomide) in combination with rituximab
-
Imbruvica (ibrutinib)
-
Umbralisib (TGR-1202)
-
Aliqopa (Copanlisib)
-
Ublituximab
-
Obinutuzumab
-
Yescarta (axicabtagene ciloleucel)
-
Keytruda (Pembrolizumab)
-
CLR 131
-
Parsaclisib
-
Nivolumab (Oppdivo)
-
Calquence (acalabrutinib)
-
Betalutin (177Lu-satetraxetan-lilotomab)
-
Navitoclax (ABT-263)
-
Orelabrutinib (ICP-022)
-
M7583
-
ARQ 531
-
Duvelisib
-
Zanubrutinib
-
Zandelisib
-
ALT-803
-
LOXO-305
-
SD-101
And many more.
Request for Sample Pages @ https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight
Table of Content
1. Report Introduction
2. Marginal Zone Lymphoma
3. Marginal Zone Lymphoma Current Treatment Patterns
4. Marginal Zone Lymphoma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Marginal Zone Lymphoma Late Stage Products (Phase-III)
7. Marginal Zone Lymphoma Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Marginal Zone Lymphoma Discontinued Products
13. Marginal Zone Lymphoma Product Profiles
14. Marginal Zone Lymphoma Key Companies
15. Marginal Zone Lymphoma Key Products
16. Dormant and Discontinued Products
17. Marginal Zone Lymphoma Unmet Needs
18. Marginal Zone Lymphoma Future Perspectives
19. Marginal Zone Lymphoma Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Visit to get the sample report: https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight
Other Latest Reports By DelveInsight
DelveInsight’s “Follicular Lymphoma Market” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). As per DelveInsight, Follicular Lymphoma Market is expected to grow immensely in the coming years owing to the active participation of key companies such as Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, BeiGene, and others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/